MDT-AP-1196
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 75
- os_event
- false
- age_years
- 2
- sex
- F
- new_clusters
- S2
- umap1_2d
- -0.845987299
- umap2_2d
- -8.198669299
- umap1_3d
- -3.727898407
- umap2_3d
- -2.582287623
- umap3_3d
- 6.060130033
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.620
- ALLOGRAFT_REJECTION+0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- INFLAMMATORY_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- COMPLEMENT+0.380
- CHOLESTEROL_HOMEOSTASIS+0.330
- IL2_STAT5_SIGNALING+0.320
- APICAL_JUNCTION+0.280
Top 10 suppressed
- PROTEIN_SECRETION-0.330
- TGF_BETA_SIGNALING-0.210
- DNA_REPAIR-0.200
- HEME_METABOLISM-0.190
- WNT_BETA_CATENIN_SIGNALING-0.190
- OXIDATIVE_PHOSPHORYLATION-0.150
- HEDGEHOG_SIGNALING-0.130
- PEROXISOME-0.010
- FATTY_ACID_METABOLISM+0.000
- NOTCH_SIGNALING+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1133 | Med | Medulloblastoma | 0.855 |
| 2 | MDT-AP-0348 | Med | Medulloblastoma | 0.852 |
| 3 | MDT-AP-2102 | Med | Medulloblastoma | 0.847 |
| 4 | 6e639239-cdae-4412-880f-ef813a956ff7 | — | — | 0.845 |
| 5 | b291037d-31f4-4303-95c9-7322950a45a7 | — | — | 0.839 |
| 6 | AUR-AFUI-TTP1-A-1-0-R-A743-41 | — | C | 0.838 |
| 7 | TCGA-BH-A0BZ-01A-31R-A12P-07 | — | C | 0.837 |
| 8 | TCGA-AR-A1AT-01A-11R-A12P-07 | — | C | 0.835 |
| 9 | MDT-AP-1106 | Med | Medulloblastoma | 0.833 |
| 10 | MDT-AP-0539 | Med | Medulloblastoma | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.620 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |